S&P 500   4,670.77 (+1.66%)
DOW   35,233.58 (+0.96%)
QQQ   399.77 (+2.19%)
AAPL   160.69 (+2.47%)
MSFT   337.36 (+2.33%)
FB   339.29 (+1.85%)
GOOGL   2,913.24 (+2.45%)
AMZN   3,575.42 (+2.02%)
TSLA   1,126.54 (+4.12%)
NVDA   330.14 (+4.80%)
BABA   131.72 (-1.22%)
NIO   40.29 (+0.75%)
CGC   11.09 (-5.13%)
AMD   160.43 (+3.63%)
GE   98.92 (+1.10%)
MU   85.83 (+2.89%)
T   23.94 (-1.16%)
F   19.71 (-0.20%)
DIS   147.83 (-0.19%)
ACB   6.42 (-5.45%)
AMC   36.52 (-2.95%)
PFE   53.06 (-1.74%)
BA   197.40 (-0.91%)
S&P 500   4,670.77 (+1.66%)
DOW   35,233.58 (+0.96%)
QQQ   399.77 (+2.19%)
AAPL   160.69 (+2.47%)
MSFT   337.36 (+2.33%)
FB   339.29 (+1.85%)
GOOGL   2,913.24 (+2.45%)
AMZN   3,575.42 (+2.02%)
TSLA   1,126.54 (+4.12%)
NVDA   330.14 (+4.80%)
BABA   131.72 (-1.22%)
NIO   40.29 (+0.75%)
CGC   11.09 (-5.13%)
AMD   160.43 (+3.63%)
GE   98.92 (+1.10%)
MU   85.83 (+2.89%)
T   23.94 (-1.16%)
F   19.71 (-0.20%)
DIS   147.83 (-0.19%)
ACB   6.42 (-5.45%)
AMC   36.52 (-2.95%)
PFE   53.06 (-1.74%)
BA   197.40 (-0.91%)
S&P 500   4,670.77 (+1.66%)
DOW   35,233.58 (+0.96%)
QQQ   399.77 (+2.19%)
AAPL   160.69 (+2.47%)
MSFT   337.36 (+2.33%)
FB   339.29 (+1.85%)
GOOGL   2,913.24 (+2.45%)
AMZN   3,575.42 (+2.02%)
TSLA   1,126.54 (+4.12%)
NVDA   330.14 (+4.80%)
BABA   131.72 (-1.22%)
NIO   40.29 (+0.75%)
CGC   11.09 (-5.13%)
AMD   160.43 (+3.63%)
GE   98.92 (+1.10%)
MU   85.83 (+2.89%)
T   23.94 (-1.16%)
F   19.71 (-0.20%)
DIS   147.83 (-0.19%)
ACB   6.42 (-5.45%)
AMC   36.52 (-2.95%)
PFE   53.06 (-1.74%)
BA   197.40 (-0.91%)
S&P 500   4,670.77 (+1.66%)
DOW   35,233.58 (+0.96%)
QQQ   399.77 (+2.19%)
AAPL   160.69 (+2.47%)
MSFT   337.36 (+2.33%)
FB   339.29 (+1.85%)
GOOGL   2,913.24 (+2.45%)
AMZN   3,575.42 (+2.02%)
TSLA   1,126.54 (+4.12%)
NVDA   330.14 (+4.80%)
BABA   131.72 (-1.22%)
NIO   40.29 (+0.75%)
CGC   11.09 (-5.13%)
AMD   160.43 (+3.63%)
GE   98.92 (+1.10%)
MU   85.83 (+2.89%)
T   23.94 (-1.16%)
F   19.71 (-0.20%)
DIS   147.83 (-0.19%)
ACB   6.42 (-5.45%)
AMC   36.52 (-2.95%)
PFE   53.06 (-1.74%)
BA   197.40 (-0.91%)
NASDAQ:ACAD

ACADIA Pharmaceuticals Stock Forecast, Price & News

$19.08
+0.29 (+1.54%)
(As of 11/29/2021 03:03 PM ET)
Add
Compare
Today's Range
$18.88
$19.49
50-Day Range
$16.61
$21.57
52-Week Range
$15.68
$57.34
Volume
17,736 shs
Average Volume
1.72 million shs
Market Capitalization
$3.07 billion
P/E Ratio
N/A
Dividend Yield
N/A
Beta
0.61
30 days | 90 days | 365 days | Advanced Chart
Receive ACAD News and Ratings via Email

Sign-up to receive the latest news and ratings for ACADIA Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.


ACADIA Pharmaceuticals logo

About ACADIA Pharmaceuticals

ACADIA Pharmaceuticals, Inc. operates as a biopharmaceutical company. It focuses on the development and commercialization of medicines to address unmet medical needs in central nervous system, or CNS, disorders. The firm's products include Nuplazid, which is used for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. The company was founded by Mark R. Brann on July 16, 1993 and is headquartered in San Diego, CA.

Headlines

10 Reddit Stocks that Flopped in 2021
November 26, 2021 |  finance.yahoo.com
ACADIA's (ACAD) Q3 Earnings and Revenues Beat Estimates
November 9, 2021 |  finance.yahoo.com
ACADIA Pharmaceuticals: Q3 Earnings Insights
November 8, 2021 |  benzinga.com
What Wall Street expects from ACADIA Pharmaceuticals's earnings
November 7, 2021 |  markets.businessinsider.com
See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ACAD
Employees
601
Year Founded
N/A

Sales & Book Value

Annual Sales
$441.76 million
Book Value
$3.53 per share

Profitability

Net Income
$-281.58 million
Pretax Margin
-40.25%

Debt

Price-To-Earnings

Miscellaneous

Free Float
114,941,000
Market Cap
$3.07 billion
Optionable
Optionable

Company Calendar

Last Earnings
11/08/2021
Today
11/29/2021
Fiscal Year End
12/31/2021
Next Earnings (Estimated)
2/23/2022

MarketRank

Overall MarketRank

2.59 out of 5 stars

Medical Sector

79th out of 1,392 stocks

Pharmaceutical Preparations Industry

31st out of 670 stocks

Analyst Opinion: 3.2Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 4.2Valuation: 0.6 5 -4 -3 -2 -1 -












ACADIA Pharmaceuticals (NASDAQ:ACAD) Frequently Asked Questions

Is ACADIA Pharmaceuticals a buy right now?

18 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for ACADIA Pharmaceuticals in the last twelve months. There are currently 12 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" ACADIA Pharmaceuticals stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ACAD, but not buy additional shares or sell existing shares.
View analyst ratings for ACADIA Pharmaceuticals
or view top-rated stocks.

How has ACADIA Pharmaceuticals' stock been impacted by Coronavirus (COVID-19)?

ACADIA Pharmaceuticals' stock was trading at $36.87 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, ACAD shares have decreased by 48.3% and is now trading at $19.07.
View which stocks have been most impacted by COVID-19
.

When is ACADIA Pharmaceuticals' next earnings date?

ACADIA Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Wednesday, February 23rd 2022.
View our earnings forecast for ACADIA Pharmaceuticals
.

How were ACADIA Pharmaceuticals' earnings last quarter?

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) issued its quarterly earnings data on Monday, November, 8th. The biopharmaceutical company reported ($0.09) EPS for the quarter, topping the Zacks' consensus estimate of ($0.26) by $0.17. The biopharmaceutical company had revenue of $131.61 million for the quarter, compared to analysts' expectations of $127.77 million. ACADIA Pharmaceuticals had a negative trailing twelve-month return on equity of 32.74% and a negative net margin of 40.38%. ACADIA Pharmaceuticals's revenue was up 9.2% on a year-over-year basis. During the same period last year, the company posted ($0.54) earnings per share.
View ACADIA Pharmaceuticals' earnings history
.

What guidance has ACADIA Pharmaceuticals issued on next quarter's earnings?

ACADIA Pharmaceuticals updated its FY 2021 earnings guidance on Monday, November, 29th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $480 million-$500 million, compared to the consensus revenue estimate of $490.42 million.

What price target have analysts set for ACAD?

18 analysts have issued twelve-month price objectives for ACADIA Pharmaceuticals' stock. Their forecasts range from $18.00 to $57.00. On average, they anticipate ACADIA Pharmaceuticals' share price to reach $27.39 in the next twelve months. This suggests a possible upside of 43.7% from the stock's current price.
View analysts' price targets for ACADIA Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

Who are ACADIA Pharmaceuticals' key executives?

ACADIA Pharmaceuticals' management team includes the following people:

What is Steve Davis' approval rating as ACADIA Pharmaceuticals' CEO?

8 employees have rated ACADIA Pharmaceuticals CEO Steve Davis on Glassdoor.com. Steve Davis has an approval rating of 88% among ACADIA Pharmaceuticals' employees.

What other stocks do shareholders of ACADIA Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ACADIA Pharmaceuticals investors own include Micron Technology (MU), NVIDIA (NVDA), Gilead Sciences (GILD), Sarepta Therapeutics (SRPT), Pfizer (PFE), Tesla (TSLA), Alibaba Group (BABA), Amarin (AMRN), Advanced Micro Devices (AMD) and Exelixis (EXEL).

What is ACADIA Pharmaceuticals' stock symbol?

ACADIA Pharmaceuticals trades on the NASDAQ under the ticker symbol "ACAD."

Who are ACADIA Pharmaceuticals' major shareholders?

ACADIA Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional investors include BlackRock Inc. (6.32%), Geode Capital Management LLC (1.26%), Janus Henderson Group PLC (1.21%), Artisan Partners Limited Partnership (0.89%), Nordea Investment Management AB (0.77%) and The Manufacturers Life Insurance Company (0.64%). Company insiders that own ACADIA Pharmaceuticals stock include Austin D Kim, Austin D Kim, Bros Advisors Lp Baker, Elena Ridloff, James M Daly, Laura Brege, Michael J Yang, Srdjan R Stankovic, Srdjan R Stankovic and Stephen Davis.
View institutional ownership trends for ACADIA Pharmaceuticals
.

Which major investors are selling ACADIA Pharmaceuticals stock?

ACAD stock was sold by a variety of institutional investors in the last quarter, including Frontier Capital Management Co. LLC, Millennium Management LLC, Skandinaviska Enskilda Banken AB publ , Geode Capital Management LLC, Caption Management LLC, Citadel Advisors LLC, Jane Street Group LLC, and California State Teachers Retirement System. Company insiders that have sold ACADIA Pharmaceuticals company stock in the last year include Austin D Kim, Elena Ridloff, Michael J Yang, Srdjan R Stankovic, and Stephen Davis.
View insider buying and selling activity for ACADIA Pharmaceuticals
or view top insider-selling stocks.

Which major investors are buying ACADIA Pharmaceuticals stock?

ACAD stock was bought by a variety of institutional investors in the last quarter, including Nordea Investment Management AB, Goldman Sachs Group Inc., Voloridge Investment Management LLC, Natixis, Balyasny Asset Management LLC, Alliancebernstein L.P., Duality Advisers LP, and Squarepoint Ops LLC.
View insider buying and selling activity for ACADIA Pharmaceuticals
or or view top insider-buying stocks.

How do I buy shares of ACADIA Pharmaceuticals?

Shares of ACAD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is ACADIA Pharmaceuticals' stock price today?

One share of ACAD stock can currently be purchased for approximately $19.07.

How much money does ACADIA Pharmaceuticals make?

ACADIA Pharmaceuticals has a market capitalization of $3.07 billion and generates $441.76 million in revenue each year. The biopharmaceutical company earns $-281.58 million in net income (profit) each year or ($1.20) on an earnings per share basis.

How many employees does ACADIA Pharmaceuticals have?

ACADIA Pharmaceuticals employs 601 workers across the globe.

What is ACADIA Pharmaceuticals' official website?

The official website for ACADIA Pharmaceuticals is www.acadia-pharm.com.

Where are ACADIA Pharmaceuticals' headquarters?

ACADIA Pharmaceuticals is headquartered at 3611 VALLEY CENTRE DRIVE SUITE 300, SAN DIEGO CA, 92130.

How can I contact ACADIA Pharmaceuticals?

ACADIA Pharmaceuticals' mailing address is 3611 VALLEY CENTRE DRIVE SUITE 300, SAN DIEGO CA, 92130. The biopharmaceutical company can be reached via phone at (858) 558-2871, via email at [email protected], or via fax at 858-558-2872.


This page was last updated on 11/29/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.